Yongbin Wu

Yongbin Wu

Auto-generated profile, based on publicly available information

Yongbin Wu

Department of Laboratory Medicine, Nanxishan Hospital of Guangxi Zhuang Autonomous Region, Guilin, China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2019 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
YWYongbin Wu
Yongbin Wu
JWJian Wen
Jian Wen
WXWeiwei Xiao
Weiwei Xiao
BZBao Zhang
Bao Zhang

1 November 2021 in Journal of Infection
Verified
Journal Article
Closed access
YWYongbin Wu
Yongbin Wu
JWJian Wen
Jian Wen
GTGuifang Tang
Guifang Tang
JZJing Zhang
Jing Zhang
JXJie Xin
Jie Xin

27 January 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
JWJian Wen
Jian Wen
YWYongbin Wu
Yongbin Wu
WWWei Wei
Wei Wei
ZLZhen Li
Zhen Li
PWPing Wang
Ping Wang
WDWenqi Dong
Wenqi Dong
Alcoholic liver disease (ALD) is an important worldwide public health issue with no satisfying treatment available since now. Here we explore the effects of recombinant human cytoglobin (rhCygb) on chronic alcohol-induced liver injury and the underlying mechanisms. In vivo studies showed that rhCygb was able to ameliorate alcohol-induced liver injury, significantly reversed increased serum index (ALT, AST, TG, TC and LDL-C) and decreased serum HDL-C. Histopathology observation of the liver of rats treated with rhCygb confirmed the biochemical data. Furthermore, rhCygb significantly inhibited Kupffer cells (KCs) proliferation and TNF-α expression in LPS-induced KCs. rhCygb also inhibited LPS-induced NADPH oxidase activity and ROS, NO and O2•− generation. These results collectively indicate that rhCygb exert the protective effect on chronic alcohol-induced liver injury through suppression of KC activation and oxidative stress. In view of its anti-oxidative stress and anti-inflammatory features, rhCygb might be a promising candidate for development as a therapeutic agent against ALD.

5 May 2025 in Virology Journal
Verified
Journal Article
Open access
PDF file
YWYongbin Wu
Yongbin Wu
GTGuifang Tang
Guifang Tang
JWJian Wen
Jian Wen
YWYing Wan
Ying Wan
YWYufei Wang
Yufei Wang
LLLing Li
Ling Li
The role of hepatitis B virus (HBV) RNA in the management of patients with chronic hepatitis B (CHB) experienced with low-level viremia (LLV) remains poorly defined. This study was designed to evaluate the prognostic utility of serum HBV RNA as a biomarker for predicting treatment outcomes in this population. A retrospective cohort analysis was conducted on 117 pediatric patients with LLV (mean age: 13.14 years; 34% female) treated with continuous entecavir (ConT) or modified regimens (switching to or combining with tenofovir disoproxil fumarate) for ≥ 120 weeks. Virological response was defined as HBV DNA < 10 IU/mL at week 120. No significant baseline differences existed between ConT and modified regimen groups. Compared to ConT, modified regimens achieved greater reductions in serum HBV DNA, HBV RNA, and quantitative HBsAg, with higher cumulative undetectable rates at week 120 (HBV DNA: ≥ 80.0%; HBV RNA: ≥ 54.8%; P < 0.05). Notably, qHBsAg levels remained elevated in most patients, with only 3 individuals achieving undetectable levels (< 0.05 IU/mL). Multivariate analysis identified higher HBV RNA levels at week 48 as an independent risk factor for non-virological response (adjusted odds ratio: 5.86; 95% confidence interval: 1.40-24.62; P = 0.016). Although HBV RNA alone was less predictive than HBV DNA (area under the receiver operating characteristic curve [AUC]: 0.76 vs. 0.80; P = 0.459), combining both markers improved prediction accuracy (AUC: 0.82; P < 0.05 vs. single markers). In children with LLV, serum HBV RNA level is an independent risk factor for non-virological response and may serve as a complementary biomarker to HBV DNA for guiding antiviral therapy adjustments.